STEP UP FOR TB

Tuberculosis (TB) is the world’s leading infectious killer. The TB community needs to wake up to this challenge and take every necessary step to adopt the right policies and tools to fight this disease which is both preventable and curable.

The clock is ticking towards the 2030 deadline to end TB agreed upon by all governments in the United Nations Sustainable Development Goals.

Many countries have yet to utilize essential tools, including the latest diagnostic technologies, medicines and treatment guidelines.

In 2017, the Stop TB Partnership and Médecins Sans Frontières (MSF) conducted a 29-country survey on the status of the adoption of the latest TB policies by countries, outlined in the Out of Step report – available at www.stepupfortb.org.

We call on countries to #StepUpforTB and urgently ensure that their policies are in line with these 15 recommendations.

JOIN THE CAMPAIGN

StepUpforTB.org | #StepUpforTB

EACH DAY

28,498 CASES
4,577 DEATHS
11,107 MISSED

EACH YEAR

10.4 million CASES
1.7 million DEATHS

In 2017, the Stop TB Partnership and Médecins Sans Frontières (MSF) conducted a 29-country survey on the status of the adoption of the latest TB policies by countries, outlined in the Out of Step report – available at www.stepupfortb.org.

We call on countries to #StepUpforTB and urgently ensure that their policies are in line with these 15 recommendations.
TB PROGRAMME CHECKLIST

How does your country’s TB programme stack up against the latest science, best practices, and international guidelines?

**DRUG REGULATION**
- NTPs use quality-assured medicines
- Patients need a prescription to access TB medicines
- TB medicines benefit from accelerated registration

75% of countries surveyed have a process of accelerated registration of DRTB medicines, including new and repurposed TB medicines

**MODELS OF CARE**
- DSTB treatment can be initiated at the primary care level, and DR-TB treatment can be initiated at the district care level
- Compulsory hospitalisation is not required
- ART is immediately available for all people diagnosed with HIV

66% of countries surveyed have guidelines in place to allow the initiation of DR-TB treatment at the district level

**DR-TB TREATMENT**
- Treatment practices are in line with WHO guidance
- TB medicines recommended by WHO for treatment of DR-TB are on the national Essential Medicines List (EML)
- New medicines are made available via import waivers until they are fully registered in the country

28% of countries surveyed have either bedaquiline or delamanid listed on their national EML

**DIAGNOSTICS**
- Nobody has to pay for a TB test out of pocket
- WHO-recommended tests (i.e. Xpert) are used as the initial diagnostic tool for all adults and children with suspected TB
- Everyone has access to second-line drug susceptibility testing (DST)

52% of countries surveyed use Xpert MTB/RIF as the initial diagnostic test for all adults and children being investigated for TB

50% of countries surveyed have adopted new paediatric TB FDCs

66% of countries surveyed have either bedaquiline or delamanid listed on their national EML

75% of countries surveyed have a process of accelerated registration of DRTB medicines, including new and repurposed TB medicines

52% of countries surveyed have either bedaquiline or delamanid listed on their national EML

**TAKE ACTION**

1. **Promote** the campaign on social media using #StepUpforTB
2. **Contact** your NTP or Minister of Health and call on them to Step Up for TB
3. **Ask** your local Parliamentarians to support the campaign

Adoption and implementation of the 15 key policies and practices identified in the report will reduce the overall global burden of TB and its drug resistant forms.

All stakeholders — including countries, manufacturers, donors and international organizations — need to work collectively to step in line with known best practices that can help win the fight to end TB.